Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
J Struct Biol. 2021 Mar;213(1):107691. doi: 10.1016/j.jsb.2020.107691. Epub 2020 Dec 31.
GTP Cyclohydrolase I (GCH1) catalyses the conversion of guanosine triphosphate (GTP) to dihydroneopterin triphosphate (H2NTP), the initiating step in the biosynthesis of tetrahydrobiopterin (BH4). BH4 functions as co-factor in neurotransmitter biosynthesis. BH4 homeostasis is a promising target to treat pain disorders in patients. The function of mammalian GCH1s is regulated by a metabolic sensing mechanism involving a regulator protein, GCH1 feedback regulatory protein (GFRP). Dependent on the relative cellular concentrations of effector ligands, BH4 and phenylalanine, GFRP binds GCH1 to form inhibited or activated complexes, respectively. We determined high-resolution structures of the ligand-free and -bound human GFRP and GCH1-GFRP complexes by X-ray crystallography. Highly similar binding modes of the substrate analogue 7-deaza-GTP to active and inhibited GCH1-GFRP complexes confirm a novel, dissociation rate-controlled mechanism of non-competitive inhibition to be at work. Further, analysis of all structures shows that upon binding of the effector molecules, the conformations of GCH1 or GFRP are altered and form highly complementary surfaces triggering a picomolar interaction of GFRP and GCH1 with extremely slow k values, while GCH1-GFRP complexes rapidly disintegrate in absence of BH4 or phenylalanine. Finally, comparing behavior of full-length and N-terminally truncated GCH1 we conclude that the disordered GCH1 N-terminus does not have impact on complex formation and enzymatic activity. In summary, this comprehensive and methodologically diverse study helps to provide a better understanding of the regulation of GCH1 by GFRP and could thus stimulate research on GCH1 modulating drugs.
三磷酸鸟苷环化水解酶 1(GTPCH1)催化鸟苷三磷酸(GTP)转化为二氢神经氨酸三磷酸(H2NTP),这是四氢生物蝶呤(BH4)生物合成的起始步骤。BH4 作为神经递质生物合成的辅助因子。BH4 动态平衡是治疗患者疼痛障碍的有希望的靶点。哺乳动物 GCH1 的功能受涉及调节蛋白 GCH1 反馈调节蛋白(GFRP)的代谢感应机制调节。依赖于效应配体 BH4 和苯丙氨酸的相对细胞浓度,GFRP 分别与 GCH1 结合形成抑制或激活复合物。我们通过 X 射线晶体学确定了配体游离和结合的人 GFRP 和 GCH1-GFRP 复合物的高分辨率结构。底物类似物 7-脱氮-GTP 对活性和抑制的 GCH1-GFRP 复合物的高度相似结合模式证实了一种新的、解离速率控制的非竞争性抑制机制在起作用。此外,所有结构的分析表明,在效应分子结合后,GCH1 或 GFRP 的构象发生改变,并形成高度互补的表面,触发 GFRP 和 GCH1 之间的皮摩尔相互作用,其 k 值极慢,而 GCH1-GFRP 复合物在没有 BH4 或苯丙氨酸的情况下迅速解体。最后,通过比较全长和 N 端截断的 GCH1 的行为,我们得出结论,无规卷曲的 GCH1 N 端不会影响复合物的形成和酶活性。总之,这项全面且方法多样的研究有助于更好地理解 GFRP 对 GCH1 的调节,从而可以刺激 GCH1 调节药物的研究。